Page 62 - Revista Argentina de Transfusión 2-2019

46. Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Inves- 63. Suryanarayan D, Schulman S. Potential antidotes for reversal
tigators. Oral rivaroxaban for symptomatic venous thromboem- of old and neworal anticoagulants. Thromb Res 2014;133(Suppl
bolism. N Engl J Med 2010;363(26):2499–2510 2): S158–S166
47. Büller HR, Prins MH, Lensin AW, et al; EINSTEIN–PE Investiga- 64. Lévy S. Newer clinically available antithrombotics and their
tors. Oral rivaroxaban for the treatment of symptomatic pul- antidotes. J Interv Card Electrophysiol 2014;40(3):269–275
monary embolism. N Engl J Med 2012;366(14):1287–1297 65. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote
48. Prins MH, Lensing AW, Bauersachs R, et al; EINSTEIN Investi- for reversal of anticoagulation by direct and indirect inhibitors
gators. Oral rivaroxaban versus standard therapy for the treat- of coagulation fac tor Xa. Nat Med 2013;19(4):446–451
ment of symptomatic venous thromboembolism: a pooled analy- 66. Hollenbach SJ, Lu G, Tan S, et al. (2012) PRT064445 but not
sis of the EINSTEIN-DVT and PE randomized studies. Thromb J recombinant FVII a reverses rivaroxaban induced anticoagula-
2013;11(1):21 tion as measured by re duction in blood loss in a rabbit liver
49. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investiga- laceration model. ASH Annual Meet Abstr120(21):3414
tors. Rivaroxaban versus warfarin in nonvalvular atrial fibrilla- 67. Crowther MA, Kitt M, McClure M, et al. Randomized, doubleblind,
tion. N Engl J Med 2011;365(10):883–891 placebocontrolled single ascending dose pharmacokinetic and
50. Fenger-Eriksen C, Münster AM, Grove EL. New oral anticoagu- pharmacodynamic study of PRT064445, a universal antidote
lants: clinical indications, monitoring and treatment of acute for factor Xa inhibitors. (abstract) Arterioscler Thromb Vasc
bleeding complications. Acta Anaesthesiol Scand 2014;58(6): Biol 2013;33(5):A10
651–659 68. Crowther MA, Kitt M, Lorenz T, et al. A phase 2 randomized,
51. Liew A, Eikelboom JW, O’Donnell M, Hart RG. Assessment of double-blind, placebo-controlled trial of PRT064445, a novel,
anticoagulation intensity and management of bleeding with universal antidote for direct and indirect factor Xa inhibitors.
old and new oral anticoagulants. Can J Cardiol 2013;29(7, Suppl): (abstract) J Thromb Haemost 2013;11(Suppl 2):AS20
S34–S44 69. Crowther MA, Mathur V, Kitt M, et al. A phase 2 randomized,
52. Pollack CV Jr.Managing bleeding in anticoagulated patients in double-blind, placebo-controlled trial demonstrating reversal
the emergency care setting. J Emerg Med 2013;45(3):467–477 of rivaroxaban in duced anticoagulation in healthy subjects by
53. Tran H, Joseph J, Young L, et al. New oral anticoagulants: a andexanet alfa (PRT064445), an antidote for FXa inhibitors. (ab-
practical guide on prescription, laboratory testing and stract) Blood 2013;122(21):A3636
periprocedural/ bleeding management. Intern Med J 2014;44(6): 70. Laulicht B, Bakhru S, Lee C, et al. Small molecule antidote for
525–536 anticoagulants. (abstract) Circulation 2012;126(21):10021
54. Siegal DM, Cuker A. Reversal of novel oral anticoagulants in 71. Laulicht B, Bakhru S, Jiang X, et al. Antidote for new oral antico-
patients with major bleeding. J Thromb Thrombolysis 2013; agulants: mechanism of action and binding specificity of
35(3):391–398. PER977. (abstract) J Thromb Haemost 2013;11(Suppl 2):AS47
55. Franchini M, Lippi G. Prothrombin complex concentrates: an 72. Xarelto (rivaroxaban) prescribing information. Titusville, NJ:
update. Blood Transfus 2010;8(3):149–154. Janssen Pharmaceuticals, Inc.; Available at: www.xareltohcp.
56. Dickneite G, Hoffman M. Reversing the new oral antico- com/sites/default/files/pdf/xarelto_0.pdf#zoom¼100.
agulants with prothrombin complex concentrates (PCCs): Accessed on October 28, 2014.
what is the evidence? Thromb Haemost 2014;111(2):189– 73. Eliquis (apixaban) prescribing information. Princeton, NJ: Bris-
198. tol- Myers Squibb Company. Available at: http://packageinserts.
57. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller bms.com/pipi_eliquis.pdf. Accessed on October 28, 2014.
HR, Levi M. Reversal of rivaroxaban and dabigatran by pro- 74. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants:
thrombin complex concentrate: a randomized, placebo-control- an overview of current developments. Thromb Haemost.
led, crossover study in healthy subjects. Circulation 2015;113: 931-942.
2011;124(14): 1573–1579. 75. Siegal DM,Curnutte JT,Connolly SJ, et al.AndexanetAlfa for the
58. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, et al. Re- reversal of factor Xa inhibitor activity. N Engl JMed.
versal of apixaban induced alterations in hemostasis by differ- 2015;373:2413-2424.
ent coagulation factor concentrates: significance of studies in 76. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant ef-
vitro with circulating human blood. PLoS ONE 2013; fects of novel oral anticoagulants: role of ciraparantag, andexanet
8(11):e78696. alfa, and idarucizumab. Vasc Health Risk Manag. 2016;12:35-44.
59. Lee FMH, Chan AKC, Lau KK, Chan HH. Reversal of new, 77. Costin J, Laulicht B, Bakhru S, Steiner S. PER977 reverses low
factorspecific oral anticoagulants by rFVIIa, prothrombin com- molecular weight heparin in addition to IIa and Xa new oral
plex concentrate and activated prothrombin complex concen- anticoagulants. J Am Coll Cardiol. 2015;65:A2056.
trate: a review of animal and human studies. Thromb Res 78. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to
2014;133(5): 705–713. reverse the anticoagulant effect of edoxaban. N Engl J Med.
60. Ebright J, Mousa SA. Oral anticoagulants and status of anti- 2014;371:2141-2142.
dotes for the reversal of bleeding risk. Clin Appl Thromb Hemost 79. Nabil K. Thalji and Rodney M. Camire. Rendering factor Xa
2015; 21(2):105–114. zymogen-like as a therapeutic strategy to treat bleeding. Curr
61. Majeed A, Schulman S. Bleeding and antidotes in new oral anti- Opin Hematol 2017, 24:453-459
coagulants. Best Pract Res Clin Haematol 2013;26(2):191–202. 80. Heidbuchel H, Verhamme P, Alings M, et al. Updated Euro-
62. Lauw MN, Coppens M, Eikelboom JW. Recent advances in anti- pean Heart Rhythm Association Practical Guide on the use of
dotes for direct oral anticoagulants: their arrival is imminent. non-vitamin K antagonist anticoagulants in patients with non-
Can J Cardiol 2014;30(4):381–384 valvular atrial fibrillation. Europace. 2015;17:1467-1507.

Pág. 146 AAHITC - Lavalleja 1214 (C1414DTZ) Vol. XLV / N° 2 / 2019 Dra. Robin, María Cristina
Cdad. Aut. de Bs. As. - Argentina Págs. 139 / 147
Tel/Fax: (54-11)4771-2501 - L.Rot.
E-mail: aahitc@aahitc.org.ar